Nagata et al. (126), revealed the anti-obesity effect of glucoraphanin, precursor of sulforaphane, in HFD-fed mice, and found that 0.3% w/w glucoraphanin for oral administration for 14 weeks significantly reduced body weight, alleviated hepatic steatosis and improved insulin sensitivity in wild type mice but not in Nrf2 KO mice. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.